Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Source: Motley Fool ↗ (cross-verified by 4 outlets — full list below)
Amgen, the biotech heavyweight with a diversified portfolio spanning oncology, inflammation and rare diseases, reported FY 2025 revenue of nearly $36.7 billion—a 9.9 percent increase from the prior year—and net income of roughly $7.7 billion, lifting its net margin to 21 percent from 12.2 percent in 2024. The company’s balance sheet as of December 2025 shows a debt‑to‑equity ratio of about 6.3 times and a current ratio of 1.1 times, while free cash flow reached close to $8.1 billion, underscoring its strong cash‑generating capacity. Amgen’s sales are heavily concentrated through three wholesalers—McKesson, Cencora and Cardinal Health—which together account for nearly 77 percent of gross revenues, a concentration that adds a layer of risk despite the firm’s profitability and its practice of returning capital to shareholders through a growing dividend.
In contrast, Revolution Medicines remains a clinical‑stage oncology company with no commercial sales, reporting zero revenue and a net loss of about $1.1 billion in FY 2025 as it expanded its trial programs. Its balance sheet reflects a very low debt‑to‑equity ratio of roughly 0.1 times and a robust current ratio of 9.5 times, but free cash flow was negative at approximately $913.7 million, typical for a firm still funding research. The company’s strategy hinges on targeting RAS‑addicted cancers, and it leverages strategic collaborations—including a partnership with BeOne Medicines and a royalty arrangement with Royalty Pharma—to finance its pipeline without diluting equity. While Revolution faces the usual high‑failure risk of early‑stage biotech and competition from larger rivals such as AstraZeneca and Pfizer, it recently achieved a breakthrough: daraxonrasib became the first targeted therapy approved for metastatic pancreatic cancer, cutting the risk of death by more than half and potentially reshaping treatment for one of the deadliest cancers.
The divergent financial profiles of the two firms present investors with a classic trade‑off between stability and speculative upside. Amgen must navigate pricing pressures from Medicare and commercial payors, ongoing IRS tax disputes over profit allocation, and the threat of biosimilar competition, yet its solid earnings, dividend growth and sizable cash flow make it a dependable choice for those seeking predictable exposure to healthcare. Revolution Medicines, while still burning cash and lacking revenue, offers the allure of a transformative oncology breakthrough that could generate substantial future earnings if its RAS‑targeted drugs succeed in broader indications such as lung cancer. The recent approval of daraxonrasib, coupled with a new partnership that supplies non‑dilutive funding, suggests a pathway toward commercial scale, but the company’s fortunes remain tied to the outcomes of clinical trials and its ability to compete against far larger pharmaceutical players. Investors must weigh Amgen’s proven cash‑generating track record against Revolution’s high‑risk, high‑reward potential when deciding which healthcare stock better fits their portfolio objectives for 2026.
⚡ Effects Interpreter
🌍World Economylow impact
What this means for you
- ▶Overseas suppliers might quietly rethink their pricing after a story like this.
- ▶Trading partners on the other side of the world could feel a distant nudge.
🏙️Local Economylow impact
What this means for you
- ▶The cost of a weekly food shop can creep up in the background.
- ▶The knock-on for local trade is usually gradual rather than sudden.
🏦Rates & Bankslow impact
What this means for you
- ▶Banks generally prefer a wait-and-see approach before touching their rates.
- ▶Savers might glance at their account rate — lenders adjust after big events.
❤️Healthlow impact
What this means for you
- ▶Trusted medical advice usually beats speculation when health news breaks.
- ▶Families touched by this might find comfort in checking the facts.
💷Wealthlow impact
What this means for you
- ▶Your budget may feel a modest health-related nudge over time.
- ▶Days lost to illness can gradually dent household income.
🏠Housingmedium impact
What this means for you
- ▶Local surveyors typically note that sentiment shifts before prices actually do.
- ▶Home costs usually respond further down the line, once the bigger picture settles.
🌍 Effects for your country
The U.S.'s central bank rate currently stands at 3.75%, so a global rates move like this could feed through to local borrowing costs. The U.S.'s economy is growing at 2.3% with inflation at 3.2%, the backdrop this story's effects play out against locally. Housing-market effects like this are usually felt most where mortgage rates track the U.S.'s own central bank rate closely. With the U.S.'s unemployment at 4.4%, personal-finance effects like this land on a labour market that is currently fairly stable. Health-system effects are harder to localise from economic indicators alone — the real impact in the U.S. depends more on local healthcare capacity than the figures above.
The UK's central bank rate currently stands at 3.75%, so a global rates move like this could feed through to local borrowing costs. The UK's economy is growing at 0.8% with inflation at 3.2%, the backdrop this story's effects play out against locally. Housing-market effects like this are usually felt most where mortgage rates track the UK's own central bank rate closely. With the UK's unemployment at 5.6%, personal-finance effects like this land on a labour market that is currently fairly stable. Health-system effects are harder to localise from economic indicators alone — the real impact in the UK depends more on local healthcare capacity than the figures above.
France's central bank rate currently stands at 2%, so a global rates move like this could feed through to local borrowing costs. France's economy is growing at 0.9% with inflation at 1.8%, the backdrop this story's effects play out against locally. Housing-market effects like this are usually felt most where mortgage rates track France's own central bank rate closely. With France's unemployment at 7.9%, personal-finance effects like this land on a labour market that is already under strain. Health-system effects are harder to localise from economic indicators alone — the real impact in France depends more on local healthcare capacity than the figures above.
Romania's central bank rate currently stands at 6.5%, so a global rates move like this could feed through to local borrowing costs. Romania's economy is growing at 0.7% with inflation at 7.8%, the backdrop this story's effects play out against locally. Housing-market effects like this are usually felt most where mortgage rates track Romania's own central bank rate closely. With Romania's unemployment at 6%, personal-finance effects like this land on a labour market that is currently fairly stable. Health-system effects are harder to localise from economic indicators alone — the real impact in Romania depends more on local healthcare capacity than the figures above.
The UAE's central bank rate currently stands at 3.65%, so a global rates move like this could feed through to local borrowing costs. The UAE's economy is growing at 3.1% with inflation at 2.5%, the backdrop this story's effects play out against locally. Housing-market effects like this are usually felt most where mortgage rates track the UAE's own central bank rate closely. Health-system effects are harder to localise from economic indicators alone — the real impact in the UAE depends more on local healthcare capacity than the figures above.